Cell Therapy

Placental-based Treatment Improved Mobility in Patients affected by Intermittent Claudication

Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, announced positive top-line results from its multinational Phase II clinical study of PLX-PAD cells in the treatment of Intermittent Claudication (IC). PLX-PAD treatment reduced Incidence of revascularization and improved patients’ mobility. Study results also validate the design of Pluristem’s ongoing Pivotal Phase III study in CLI, a more severe stage of peripheral arterial disease (PAD) and confirm Pluristem’s proprietary
Cell Therapy

$8.7 Million Awarded to Support Phase III Femoral Neck Fracture Trial by EU Horizon 2020 Program

Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, announced today that its Phase III study of PLX-PAD cells to support recovery following surgery for femoral neck fracture has been awarded an $8.7 million (7.4 million Euro) non-dilutive grant from the Horizon 2020 program, the European Union’s largest research and innovation program. Final approval of the grant is subject to the finalization of the consortium and Horizon 2020